This trial is testing the safety and side effects of a chemotherapy drug, cyclophosphamide, given with a corticosteroid drug, dexamethasone, to treat patients with castration resistant prostate cancer that has spread to other parts of the body.
- Castration-resistant Prostate Cancer
- Stage IVB Prostate Cancer
- Prostate Cancer
2 Primary · 4 Secondary · Reporting Duration: From date of treatment initiation to PSA progression (as defined by Prostate Cancer Working Group 2 [PCWG2]), an average of up to 4 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (cyclophosphamide, dexamethasone)
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Cyclophosphamide · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Cyclophosphamide been cleared by the FDA?
"Cyclophosphamide's lack of extensive clinical data only warrants a score of 1 in terms of safety." - Anonymous Online Contributor
Are new patients being signed up for this treatment study?
"The listed clinical trial on clinicaltrials.gov is actively searching for participants. The study was originally posted on 6/29/2022 and was last edited on 10/8/2022." - Anonymous Online Contributor